Published in Exp Cell Res on February 20, 2006
Long noncoding RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci (2010) 2.34
Canonical RTK-Ras-ERK signaling and related alternative pathways. WormBook (2013) 1.03
Extending the family table: Insights from beyond vertebrates into the regulation of embryonic development by FGFs. Birth Defects Res C Embryo Today (2010) 0.86
Analysis of Thisbe and Pyramus functional domains reveals evidence for cleavage of Drosophila FGFs. BMC Dev Biol (2010) 0.81
The nucleolus of Caenorhabditis elegans. J Biomed Biotechnol (2012) 0.80
Direct and heterologous approaches to identify the LET-756/FGF interactome. BMC Genomics (2006) 0.80
Global Developmental Gene Programing Involves a Nuclear Form of Fibroblast Growth Factor Receptor-1 (FGFR1). PLoS One (2015) 0.80
Evidence-Based Theory for Integrated Genome Regulation of Ontogeny-An Unprecedented Role of Nuclear FGFR1 Signaling. J Cell Physiol (2016) 0.78
NGF-induced cell differentiation and gene activation is mediated by integrative nuclear FGFR1 signaling (INFS). PLoS One (2013) 0.78
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
International network of cancer genome projects. Nature (2010) 20.35
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol (2009) 4.18
Dynamic multiple-target tracing to probe spatiotemporal cartography of cell membranes. Nat Methods (2008) 3.46
How basal are triple-negative breast cancers? Int J Cancer (2008) 3.18
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Dynamic molecular confinement in the plasma membrane by microdomains and the cytoskeleton meshwork. EMBO J (2006) 2.87
Integrated profiling of basal and luminal breast cancers. Cancer Res (2007) 2.86
Fluorescence correlation spectroscopy diffusion laws to probe the submicron cell membrane organization. Biophys J (2005) 2.57
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res (2006) 2.52
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res (2005) 2.26
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol (2008) 2.12
Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene (2004) 2.09
Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res (2005) 2.05
A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat (2010) 2.03
Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res (2005) 1.96
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer (2010) 1.93
CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A (2011) 1.91
Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol (2002) 1.89
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood (2012) 1.88
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat (2010) 1.81
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res (2006) 1.75
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood (2008) 1.74
Junctional recruitment of mammalian Scribble relies on E-cadherin engagement. Oncogene (2005) 1.73
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol (2010) 1.71
Dendritic cell aggresome-like induced structures are dedicated areas for ubiquitination and storage of newly synthesized defective proteins. J Cell Biol (2004) 1.69
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer (2008) 1.66
Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res (2004) 1.61
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer (2006) 1.58
Diffusion analysis within single nanometric apertures reveals the ultrafine cell membrane organization. Biophys J (2006) 1.56
Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle (2009) 1.56
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol (2012) 1.56
Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer (2011) 1.54
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol (2004) 1.53
Genome profiling of ERBB2-amplified breast cancers. BMC Cancer (2010) 1.53
Peyer's patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology (2011) 1.51
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer (2012) 1.47
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med (2011) 1.47
Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene (2002) 1.44
CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res (2009) 1.41
Breast cancer stem cells: tools and models to rely on. BMC Cancer (2009) 1.38
MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet (2012) 1.38
Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet (2002) 1.37
Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer (2003) 1.34
TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene (2003) 1.33
Palmitoylation is required for efficient Fas cell death signaling. EMBO J (2006) 1.33
Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene (2004) 1.31
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res (2013) 1.30
Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. Sci Signal (2011) 1.30
Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer (2007) 1.30
Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol (2005) 1.27
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One (2011) 1.27
Alteration of cohesin genes in myeloid diseases. Am J Hematol (2010) 1.26
Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res (2009) 1.26
Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res (2008) 1.26
Myeloid malignancies: mutations, models and management. BMC Cancer (2012) 1.24
Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer (2011) 1.22
Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J Clin Endocrinol Metab (2004) 1.19
Reasons for breast cancer heterogeneity. J Biol (2008) 1.17
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood (2013) 1.16
Detecting nanodomains in living cell membrane by fluorescence correlation spectroscopy. Annu Rev Phys Chem (2011) 1.15
How different are luminal A and basal breast cancers? Int J Cancer (2009) 1.15
High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. PLoS One (2011) 1.14
Lipid rafts and the initiation of T cell receptor signaling. Semin Immunol (2005) 1.14
ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res (2013) 1.14
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer (2008) 1.13
Gene expression profiling and prediction of clinical outcome in ovarian cancer. Crit Rev Oncol Hematol (2009) 1.13
Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells (2012) 1.13
Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res (2009) 1.12
An evolutionary history of the FGF superfamily. Bioessays (2005) 1.11
Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Am J Hematol (2012) 1.11
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res (2013) 1.10
Gene expression profiling and clinical outcome in breast cancer. OMICS (2006) 1.10
Control of ciliogenesis by FOR20, a novel centrosome and pericentriolar satellite protein. J Cell Sci (2010) 1.10
T-cell antigen receptor triggering and lipid rafts: a matter of space and time scales. Talking Point on the involvement of lipid rafts in T-cell activation. EMBO Rep (2008) 1.09
Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res (2011) 1.09
Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood (2003) 1.09
Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood (2003) 1.09
Moesin expression is a marker of basal breast carcinomas. Int J Cancer (2007) 1.09
High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer (2012) 1.08
Aurora B -TACC1 protein complex in cytokinesis. Oncogene (2004) 1.07
Gene expression profiling of inflammatory breast cancer. Cancer (2010) 1.07
A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res (2004) 1.07
Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene (2004) 1.07
Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol Psychiatry (2005) 1.07
Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteomics (2006) 1.07
Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood (2002) 1.06
Interaction between Erbin and a Catenin-related protein in epithelial cells. J Biol Chem (2001) 1.05
The LAP family: a phylogenetic point of view. Trends Genet (2002) 1.05
Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica (2013) 1.04
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics (2008) 1.04
Loss, mutation and deregulation of L3MBTL4 in breast cancers. Mol Cancer (2010) 1.04